What are the bleeding disorders that do not affect Prothrombin Time (PT) or Partial Thromboplastin Time (PTT)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 31, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Bleeding disorders with no PT/PTT changes can be caused by several conditions, including von Willebrand disease, platelet disorders, factor XIII deficiency, and vascular disorders, which require specialized testing and treatment beyond routine coagulation tests. These conditions can present with mucocutaneous bleeding, delayed bleeding, and poor wound healing, despite normal PT/PTT values. According to the study by 1, von Willebrand disease and factor XIII deficiency are not reliably detected by PT/PTT screening tests, and mild deficiencies in factor VIII or factor IX may not cause abnormalities in the aPTT but can still result in significant bleeding.

The diagnosis of these conditions requires specialized testing, including platelet function assays, von Willebrand factor antigen and activity levels, factor XIII assays, and bleeding time tests. As recommended by 1, flow cytometry screening should be carried out on resting platelets using antibodies against specific glycoproteins, and second-step tests may include light transmission aggregometry with an expanded agonist panel and measurement of serum TxB2.

Treatment varies by condition, and DDAVP (desmopressin) at 0.3 mcg/kg is recommended for vWD Type 1, while platelet transfusions and specific factor concentrates may be necessary for other conditions. Antifibrinolytics like tranexamic acid (10-15 mg/kg TID) can be used as adjunctive therapy for mucosal bleeding. It is essential to consult with a pediatric hematologist for accurate diagnosis and treatment of these conditions, as individual patient characteristics can affect the results of diagnostic tests.

Some key conditions to consider include:

  • von Willebrand disease
  • Platelet disorders, such as immune thrombocytopenic purpura and qualitative platelet function disorders
  • Factor XIII deficiency
  • Vascular disorders, such as hereditary hemorrhagic telangiectasia and Ehlers-Danlos syndrome
  • Mild hemophilia A or B, which may present with normal screening tests despite clinical bleeding.

In clinical practice, it is crucial to prioritize the diagnosis and treatment of these conditions to prevent significant bleeding and improve patient outcomes, as highlighted by the study 1.

From the Research

Bleeding Disorders with No PT/PTT Changes

Bleeding disorders can be complex and varied, making diagnosis and management challenging 2. Some bleeding disorders, such as von Willebrand disease (VWD) and platelet disorders, do not present with changes in prothrombin time (PT) or partial thromboplastin time (PTT).

Types of Bleeding Disorders

  • Von Willebrand Disease (VWD): a common inherited bleeding disorder characterized by a deficiency or dysfunction of von Willebrand factor (VWF) 2, 3.
  • Platelet-Type Von Willebrand Disease (PT-VWD): a rare autosomal dominant bleeding disorder caused by gain-of-function mutations in the platelet GP1BA gene, leading to platelet hyperresponsiveness 4, 5, 6.

Characteristics of PT-VWD

  • Clinical Presentation: mild to moderate mucocutaneous bleeding, which can worsen during pregnancy or with antiplatelet drugs 5, 6.
  • Laboratory Features: low VWF:ristocetin cofactor, low or normal VWF:antigen, and enhanced ristocetin-induced platelet agglutination (RIPA) 5, 6.
  • Diagnosis: simplified RIPA mixing assays, cryoprecipitate challenge, flow cytometry, and genetic testing to identify mutations in the GP1BA gene 4, 6.

Treatment of PT-VWD

  • Platelet Transfusions: effective treatment for PT-VWD, as they can help increase platelet count and reduce bleeding risk 4.
  • Von Willebrand Factor-Rich Concentrates: may be used if VWF levels are low, but platelet transfusions are preferred 4.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

von Willebrand disease and platelet disorders.

Haemophilia : the official journal of the World Federation of Hemophilia, 2014

Research

Von Willebrand factor and disease: a review for laboratory professionals.

Critical reviews in clinical laboratory sciences, 2022

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.